16 results about "Tuberculosis prophylaxis" patented technology

The invention provides a tuberculosis mRNA vaccine as well as a preparation method and application thereof. The invention firstly provides an antigen, which comprises the following antigen components: at least one fusion protein or chimeric protein formed by mycobacterium tuberculosis early secretion antigens Ag85A and Ag85B and / or immunocompetence fragments thereof, at least one mycobacterium tuberculosis PE / PPE family antigen Rv1759c (PE-PGRS family protein WAG22) or immunocompetence fragments thereof, and at least one immunocompetence fragment thereof, and at least one mycobacterium tuberculosis latent associated antigen Rv1813c or an immunocompetence fragment thereof; selectively, two or more of these antigens or immunocompetent fragments thereof may form a fusion protein and / or chimeric protein as an antigen component. The mRNA vaccine with multiple antigen components has a more effective effect on prevention of tuberculosis.

The present application provides a tuberculosis vaccine based on bovine beta defensin 5 and its application in preventing tuberculosis, which comprises a fusion protein of tuberculosis AH antigen and bovine beta defensin 5 or a coding sequence thereof. The present application fuses and expresses Ag85A and HspX, which are surface dominant antigens of Mycobacterium tuberculosis, and an optimized sequence of bovine beta defensin 5, and then purifies the protein to mix with poly I:C to prepare a fusion protein vaccine AHB-P. Or the coding sequence of the fusion gene is optimized and then connected to a vector pVAX1 to prepare a fusion DNA vaccine pVAX1-AHB. The respiratory mucosa of mice is immunized with the two fusion vaccines, and it is proved that the two fusion vaccines can enhance the body's resistance to tuberculosis infection.

The present disclosure is directed to the generation and use of a synthetic tetrasaccharide designed based on a portion of a mycobacterial polar glycolipid as a vaccine antigen to limit or prevent tuberculosis infections.

An aspect provides a vaccine composition for preventing tuberculosis comprising chorismate mutase. The vaccine composition alone may induce immunity specific to Mycobacterium tuberculosis, and when provided together with an immune adjuvant, the vaccine composition may induce immunity specific to tuberculosis more effectively. Furthermore, when an existing vaccine for tuberculosis is used as a prime and the vaccine composition according to an aspect including chorismite mutase is provided as a booster, the immunity specific to tuberculosis may be induced significantly more effectively.

The present application provides a fusion protein containing PstS1 fragment and Ag85A fragment and a tuberculosis subunit vaccine. The fusion protein comprises a first peptide segment containing Ag85A fragment, a second peptide segment containing PstS1 fragment, and the first peptide segment is connected with the second peptide segment; the subunit vaccine comprises the fusion protein. The fusion protein can stimulate cellular immunity and humoral immunity of the body at the same time, and improve the ability of the body to kill Mycobacterium tuberculosis, and the subunit vaccine can effectively prevent tuberculosis.

The invention relates to a recombinant Mycobacterium cell for use as a safe and effective vaccine in the prevention of tuberculosis occurrence or recurrence.

The invention provides a tuberculosis mRNA vaccine as well as a preparation method and application thereof. The invention firstly provides an antigen which comprises the following antigen components: at least one fusion protein or chimeric protein formed by mycobacterium tuberculosis early secretion antigens Ag85A and Ag85B and / or immunocompetence fragments thereof, and at least one mycobacterium tuberculosis PE / PPE family antigen Rv3872 (PE35) or immunocompetence fragments thereof, and at least one mycobacterium tuberculosis latent associated antigen Rv1813c or an immunocompetence fragment thereof; selectively, two or more of these antigens or immunocompetent fragments thereof may form a fusion protein and / or chimeric protein as an antigen component. The mRNA vaccine with multiple antigen components has a more effective effect on prevention of tuberculosis.

We will provide a new vaccine to prevent TB. [Solution] The present invention relates to a freeze-dried composition comprising a Mycobacterium tuberculosis complex, preferably a clinical isolate of M. tuberculosis, more preferably a clinical isolate of M. tuberculosis (MTBVAC strain), characterized by comprising a PhoP-phenotype due to inactivation by genetic deletion of the Rv0757 gene and a PDIM-phenotype due to deletion of a second gene Rv2930 (fadD26) that inhibits PDIM production, and sucrose and sodium glutamate as stabilizers or excipients. Furthermore, the present invention relates to a reconstituted composition obtained by adding water, preferably sterile water for injection, to the freeze-dried composition. The present invention relates to the composition to be used as a prophylactic agent for people at risk of infection with M. tuberculosis, or as a secondary drug for treating infected tuberculosis patients.

The application provides an improved recombinant bacillus Calmette-Guerin (BCG) and application thereof, and belongs to the technical field of biotechnology. The BCG ManLAM mutant strain is obtained by knocking out the coding gene of a key glycosyltransferase MptC for synthesizing the terminal mannose of ManLAM in the BCG, and is used as the improved BCG. Compared with the wild-type BCG, the improved BCG constructed in the application can promote the functional maturation of dendritic cells and improve the anti-tuberculosis infection immune response, can be used as a new vaccine for preventing tuberculosis or as an active ingredient for preparing a medicine for preventing and treating tuberculosis, and has a wide prospect in the development and clinical application of the new vaccine. In addition, the application provides a new tool and idea for the prevention and treatment of tuberculosis.

An mRNA tuberculosis vaccine, a preparation method therefor, and a use thereof. First, provided is an antigen, comprising the following antigen components: a fusion protein or chimeric protein formed by at least one Mycobacterium tuberculosis early secreted antigen Ag85a, Ag85b and / or an immunologically active fragment thereof, at least one Mycobaterium tuberculosis PE / PPE family antigen Rv3872 (PE35) or an immunologically active fragment thereof, and at least one Mycobacterium tuberculosis latency-associated antigen Rv1813c or an immunologically active fragment thereof; selectively, two or more of these antigens or immunologically active fragments thereof can form a fusion protein and / or a chimeric protein as antigen components. By means of multiple antigen components, mRNA vaccines are more effective in preventing tuberculosis.

The invention provides a tuberculosis mRNA vaccine as well as a preparation method and application thereof. The invention firstly provides an antigen which comprises the following antigen components: at least one mycobacterium tuberculosis early secretion antigen or an immunocompetence fragment thereof, at least one mycobacterium tuberculosis PE / PPE family antigen or an immunocompetence fragment thereof, and at least one mycobacterium tuberculosis latent associated antigen or an immunocompetence fragment thereof; selectively, two or more of these antigens or immunocompetent fragments thereof may form a fusion protein and / or chimeric protein as an antigen component. The mRNA vaccine with multiple antigen components has a more effective effect on prevention of tuberculosis.

Aspects of the present disclosure provide for improved Mycobacterium tuberculosis vaccine compositions of ionizable lipid nanoparticles for the delivery of immunogenic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in dendritic cells. In some embodiments, the incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation provided high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Other aspects of the present disclosure provide mRNA that encodes for concatenated peptides encoding for multiple MHC-II tuberculosis epitopes, and optionally includes a second mRNA encoding for concatenated MHC-I tuberculosis epitopes.

Provided are a tuberculosis mRNA vaccine, and a preparation method therefor and the use thereof. Provided is an antigen, comprising the following antigen components: at least one Mycobacterium tuberculosis early-secreted antigen or an immunologically active fragment thereof, at least one Mycobacterium tuberculosis PE / PPE family antigen or an immunologically active fragment thereof, and at least one Mycobacterium tuberculosis antigen latency-associated antigen or an immunologically active fragment thereof. Optionally, two or more of the antigens or immunologically active fragments thereof may form a fusion protein and / or a chimeric protein as an antigen component. The mRNA vaccine having various antigen components provides more effective preventive effects against tuberculosis.

This invention relates to an anti-Mycobacterium tuberculosis (Mtb) protein polypeptide and its applications, belonging to the field of biomedicine. Specifically, it discloses a Mycobacterium tuberculosis protein polypeptide Mce3A-P6 and its applications. This invention proposes that the Mce3A-P6 polypeptide and antibodies prepared using the Mce3A-P6 polypeptide as an antigen can effectively block the interaction between Mce3A and the host cell receptor GPR108, thereby significantly preventing Mtb invasion of host cells and ultimately inhibiting the Mtb infection process. Therefore, it has clinical application value in the treatment or prevention of tuberculosis.

The invention provides a tuberculosis mRNA vaccine as well as a preparation method and application thereof. The invention firstly provides an antigen which comprises the following antigen components: at least one fusion protein or chimeric protein formed by mycobacterium tuberculosis early secretion antigens Ag85A and Ag85B and / or immunocompetence fragments thereof, and at least one mycobacterium tuberculosis PE / PPE family antigen Rv2770c (PPE44) or immunocompetence fragments thereof, and at least one mycobacterium tuberculosis latent associated antigen Rv2029c or an immunocompetence fragment thereof; selectively, two or more of these antigens or immunocompetent fragments thereof may form a fusion protein and / or chimeric protein as an antigen component. The mRNA vaccine with multiple antigen components has a more effective effect on prevention of tuberculosis.

This invention discloses a monoclonal antibody that blocks the invasion of Mycobacterium tuberculosis and its application, belonging to the field of biomedicine. This invention provides a hybridoma cell line, Mce3A 15G4, which can secrete a Mce3A monoclonal antibody. This antibody specifically recognizes the Mce3A protein on the surface of Mycobacterium tuberculosis, thereby blocking the binding of Mce3A to its host cell surface receptor GPR108. The Mce3A monoclonal antibody disclosed in this invention can effectively block the process of Mycobacterium tuberculosis invading host cells, thereby effectively inhibiting the establishment of infection by Mycobacterium tuberculosis, and thus has potential clinical application value for the treatment or prevention of tuberculosis.